Marshall Thomas Holland, MD, MS | |
619 19th St S, Birmingham, AL 35233-1900 | |
(205) 934-4011 | |
Not Available |
Full Name | Marshall Thomas Holland |
---|---|
Gender | Male |
Speciality | Neurosurgery |
Experience | 11 Years |
Location | 619 19th St S, Birmingham, Alabama |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1689011421 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207T00000X | Neurological Surgery | 42498 (Alabama) | Secondary |
207T00000X | Neurological Surgery | R-9660 (Iowa) | Secondary |
207T00000X | Neurological Surgery | MD198442 (Oregon) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
University Of Alabama Hospital | Birmingham, AL | Hospital |
Callahan Eye Hospital | Birmingham, AL | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
University Of Alabama Health Services Foundation, Pc | 1951213107 | 2344 |
News Archive
In the age of coronavirus, Americans are being told to stay home and wear masks outside. The federal government has made way for hospitals to treat patients in repurposed hotels and dormitories. Private companies are working to push out new diagnostic tests.
Genetic testing may soon prove that prevention is better than cure. However, the emerging practice could have certain less desirable ethical and practical implications.
Findings from the latest PreSCD II analysis show that patients protected against sudden cardiac death by an implantable cardioverter defibrillator (ICD) one month or more after MI showed a non-significantRemarkably," says investigator Professor Heinz Völler from the Klinik am See in Ruedersdorf, Germany, "we observed in the data a survival benefit that increased with the time interval between MI and ICD implantation."
As reported recently in the journal Hepatology, WIN-R, a multicenter study of over 5,000 patients with hepatitis C virus (HCV) showed treatment with weight-based REBETOL ribavirin, USP) (RBV) in combination with pegylated interferon (PEG-IFN) alfa-2b achieved significantly higher rates of sustained virologic response (SVR) and lower relapse rates compared to combination therapy using a flat dose of RBV 800 mg/day. Superior response was found particularly in patients with the most difficult-to-treat form of the disease, genotype 1 HCV. Efficacy was consistent across all weight groups.
› Verified 4 days ago
Entity Name | University Of Alabama Health Services Foundation, Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1093768723 PECOS PAC ID: 1951213107 Enrollment ID: O20031105000261 |
News Archive
In the age of coronavirus, Americans are being told to stay home and wear masks outside. The federal government has made way for hospitals to treat patients in repurposed hotels and dormitories. Private companies are working to push out new diagnostic tests.
Genetic testing may soon prove that prevention is better than cure. However, the emerging practice could have certain less desirable ethical and practical implications.
Findings from the latest PreSCD II analysis show that patients protected against sudden cardiac death by an implantable cardioverter defibrillator (ICD) one month or more after MI showed a non-significantRemarkably," says investigator Professor Heinz Völler from the Klinik am See in Ruedersdorf, Germany, "we observed in the data a survival benefit that increased with the time interval between MI and ICD implantation."
As reported recently in the journal Hepatology, WIN-R, a multicenter study of over 5,000 patients with hepatitis C virus (HCV) showed treatment with weight-based REBETOL ribavirin, USP) (RBV) in combination with pegylated interferon (PEG-IFN) alfa-2b achieved significantly higher rates of sustained virologic response (SVR) and lower relapse rates compared to combination therapy using a flat dose of RBV 800 mg/day. Superior response was found particularly in patients with the most difficult-to-treat form of the disease, genotype 1 HCV. Efficacy was consistent across all weight groups.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Marshall Thomas Holland, MD, MS Po Box 55310, Birmingham, AL 35255-5310 Ph: () - | Marshall Thomas Holland, MD, MS 619 19th St S, Birmingham, AL 35233-1900 Ph: (205) 934-4011 |
News Archive
In the age of coronavirus, Americans are being told to stay home and wear masks outside. The federal government has made way for hospitals to treat patients in repurposed hotels and dormitories. Private companies are working to push out new diagnostic tests.
Genetic testing may soon prove that prevention is better than cure. However, the emerging practice could have certain less desirable ethical and practical implications.
Findings from the latest PreSCD II analysis show that patients protected against sudden cardiac death by an implantable cardioverter defibrillator (ICD) one month or more after MI showed a non-significantRemarkably," says investigator Professor Heinz Völler from the Klinik am See in Ruedersdorf, Germany, "we observed in the data a survival benefit that increased with the time interval between MI and ICD implantation."
As reported recently in the journal Hepatology, WIN-R, a multicenter study of over 5,000 patients with hepatitis C virus (HCV) showed treatment with weight-based REBETOL ribavirin, USP) (RBV) in combination with pegylated interferon (PEG-IFN) alfa-2b achieved significantly higher rates of sustained virologic response (SVR) and lower relapse rates compared to combination therapy using a flat dose of RBV 800 mg/day. Superior response was found particularly in patients with the most difficult-to-treat form of the disease, genotype 1 HCV. Efficacy was consistent across all weight groups.
› Verified 4 days ago
Walter J Oakes, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 619 19th Street South, Birmingham, AL 35233 Phone: 205-934-6600 | |
Charles H Clark Iii, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 800 St Vincents Drive, #700, Birmingham, AL 35205 Phone: 205-933-8981 Fax: 205-930-0746 | |
Walter George Haynes Iii, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 513 Brookwood Blvd, Ste. 75, Birmingham, AL 35209 Phone: 205-250-6805 Fax: 205-250-6580 | |
Dr. Brandon G Rocque, M.D. Neurological Surgery Medicare: Medicare Enrolled Practice Location: 1600 7th Ave S, Lowder 400, Birmingham, AL 35233 Phone: 205-638-9653 | |
Matthew Scott Erwood, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 800 Saint Vincents Dr Ste 700, Birmingham, AL 35205 Phone: 205-933-8981 Fax: 205-930-0746 | |
Dr. Chad Claus, D.O. Neurological Surgery Medicare: Medicare Enrolled Practice Location: 619 19th St S, Birmingham, AL 35249 Phone: 205-934-4011 | |
James Michael Johnston Jr., M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1600 7th Ave S, Birmingham, AL 35233 Phone: 205-939-9100 |